Phyllis I Spuls
Overview
Explore the profile of Phyllis I Spuls including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
1828
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diaz M, Curtis K, Tran J, Spuls P, Montanez-Wiscovich M, Lipner S
Dermatology
. 2025 Mar;
:1-6.
PMID: 40031878
No abstract available.
2.
International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study
Caron A, van Huizen A, Musters A, Gerbens L, Middelkamp Hup M, Flohr C, et al.
J Eur Acad Dermatol Venereol
. 2024 Aug;
39(2):331-339.
PMID: 39087636
Background: Despite the widespread off-label use of methotrexate (MTX) for the treatment of atopic dermatitis (AD), there is limited high-quality evidence on dosing regimens and existing guidelines do not provide...
3.
Drucker A, Lam M, Prieto-Merino D, Malek R, Ellis A, Yiu Z, et al.
JAMA Dermatol
. 2024 Jul;
160(9):936-944.
PMID: 39018058
Importance: There are multiple approved systemic treatments for atopic dermatitis. Lebrikizumab is a newly licensed biologic medication that has been compared to placebo in clinical trials but not to other...
4.
Li A, Musters A, Hyseni A, Gerbens L, Spuls P
Br J Dermatol
. 2024 Jul;
191(6):1012-1013.
PMID: 39005169
No abstract available.
5.
Korte E, Pasmooij A, Bolling M, Hickey S, Hussain S, Kiritsi D, et al.
Br J Dermatol
. 2024 Jun;
191(3):463-465.
PMID: 38865426
No abstract available.
6.
Stor M, Lokhorst M, Horbach S, Luijten M, Spuls P, van der Horst C
Br J Dermatol
. 2024 May;
191(5):728-736.
PMID: 38805691
Background: Evidence-based guidelines for the treatment of vascular malformations (VMs) are not readily available, possibly due to the diversity in methods used to evaluate treatment efficacy in clinical research, complicating...
7.
Jacobson M, Leshem Y, Apfelbacher C, Spuls P, Gerbens L, Thomas K, et al.
JAMA Dermatol
. 2024 May;
160(8):878-886.
PMID: 38776110
Importance: Outcome measurement is an essential component of value-based health care and can aid patient care, quality improvement, and clinical effectiveness evidence generation. The Harmonising Outcome Measures for Eczema Clinical...
8.
Stalman E, Wieske L, Keijser J, van Dam K, Kummer L, Wilbrink M, et al.
J Allergy Clin Immunol
. 2024 May;
154(3):754-766.e7.
PMID: 38763170
Background: Despite impaired humoral response in patients treated with immunosuppressants (ISPs), recent studies found similar severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection compared to controls. One...
9.
Ahmed A, Koza E, Shi V, Ma M, Haq M, Kottner J, et al.
Arch Dermatol Res
. 2024 Mar;
316(4):109.
PMID: 38498269
No abstract available.
10.
Valk A, Keijser J, van Dam K, Stalman E, Wieske L, Steenhuis M, et al.
Allergy
. 2024 Mar;
79(7):1952-1961.
PMID: 38439527
Background: The noninflammatory immunoglobulin G4 (IgG4) is linked to tolerance and is unique to humans. Although poorly understood, prolonged antigenic stimulation and IL-4-signaling along the T helper 2-axis may be...